# Philip Van Damme

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/philip-van-damme/

## Facts

| Field | Value |
| --- | --- |
| Citations | 30,018 |
| Field | Amyotrophic Lateral Sclerosis Research |
| h-index | 88 |
| i10-index | 311 |
| Last Known Institution | Allen Institute for Brain Science |
| OpenAlex ID | https://openalex.org/A5013023361 |
| ORCID iD | https://orcid.org/0000-0002-4010-2357 |
| Works | 537 |

## Researcher papers

- [EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force](https://scholariq.org/papers/efns-guidelines-on-the-clinical-management-of-amyotrophic-lateral-sclerosis-mals/)
- [Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS](https://scholariq.org/papers/trial-of-antisense-oligonucleotide-tofersen-for-i-sod1-i-als/)
- [Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study](https://scholariq.org/papers/safety-and-efficacy-of-eculizumab-in-anti-acetylcholine-receptor-antibody/)
- [Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS](https://scholariq.org/papers/phase-1-2-trial-of-antisense-oligonucleotide-tofersen-for-i-sod1-i-als/)
- [Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model](https://scholariq.org/papers/prognosis-for-patients-with-amyotrophic-lateral-sclerosis-development-and/)
- [HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients](https://scholariq.org/papers/hdac6-inhibition-reverses-axonal-transport-defects-in-motor-neurons-derived-from/)
- [Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study](https://scholariq.org/papers/age-at-symptom-onset-and-death-and-disease-duration-in-genetic-frontotemporal/)
- [The C9ORF72 expansion mutation is a common cause of ALS+/−FTD in Europe and has a single founder](https://scholariq.org/papers/the-c9orf72-expansion-mutation-is-a-common-cause-of-als-ftd-in-europe-and-has-a/)
- [Loss of <i>TBK1</i> is a frequent cause of frontotemporal dementia in a Belgian cohort](https://scholariq.org/papers/loss-of-i-tbk1-i-is-a-frequent-cause-of-frontotemporal-dementia-in-a-belgian/)
- [Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk](https://scholariq.org/papers/low-frequency-and-rare-coding-variation-contributes-to-multiple-sclerosis-risk/)
- [Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility](https://scholariq.org/papers/genome-wide-association-analyses-identify-new-brugada-syndrome-risk-loci-and/)

## Researcher topics

- [Amyotrophic Lateral Sclerosis Research](https://scholariq.org/topics/amyotrophic-lateral-sclerosis-research/)
- [Neurogenetic and Muscular Disorders Research](https://scholariq.org/topics/neurogenetic-and-muscular-disorders-research/)
- [Genetic Neurodegenerative Diseases](https://scholariq.org/topics/genetic-neurodegenerative-diseases/)
- [Parkinson's Disease Mechanisms and Treatments](https://scholariq.org/topics/parkinson-s-disease-mechanisms-and-treatments/)
- [Alzheimer's disease research and treatments](https://scholariq.org/topics/alzheimer-s-disease-research-and-treatments/)

## Researcher university

- [Allen Institute for Brain Science](https://scholariq.org/institutions/allen-institute-for-brain-science/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.